To the full analysis
Treace Medical Concepts stock: growth
TMCITreace Medical Concepts reported $212.69M in revenue for fiscal 2025, up 1.6% on the prior year, up 30% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
32.4%
per year from 2019 to 2025, per share 27.8%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | 30.0% | 32.4% |
| Revenue per share | 24.6% | 27.8% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $39.42M | −$4.27M | −$8.88M |
| 2020 | $57.37M | −$3.67M | −$5.56M |
| 2021 | $94.42M | −$20.55M | −$19.9M |
| 2022 | $141.84M | −$42.82M | −$45.49M |
| 2023 | $187.12M | −$49.53M | −$46.03M |
| 2024 | $209.36M | −$55.74M | −$48.76M |
| 2025 | $212.69M | −$59M | −$29.49M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.